GAIN-(L): Efficacy and biomarker findings of RG7160 (GA201), a novel, dual-acting monoclonal antibody (mAb) designed to enhance antibody-dependent cellular cytotoxicity (ADCC), in combination with first-line cisplatin and pemetrexed in metastatic nonsquamous NSCLC.
James Spicer(King's College London), Luis Paz‐Ares(Hospital Universitario 12 De Octubre), Vanesa Gregorc(IRCCS Ospedale San Raffaele), I. López Calderero(Instituto de Biomedicina de Sevilla), Marion Ott(Roche (Switzerland)), Luisa Mariconti(Roche (Switzerland)), Cristina Sorlini, Maria Longauer Banholzer(Roche (Switzerland)), David Carlile(Roche (Switzerland)), Enriqueta Felip(Institut Català d'Ornitologia), Ana Montes(Guy's and St Thomas' NHS Foundation Trust), Pablo Martínez(Sumitomo Dainippon Pharma (United States)), Luigi Manenti(Roche (Switzerland)), Lionel Bosquée(Centre Hospitalier Universitaire de Liège), Sophie Golding(Roche (Switzerland)), A. Passioukov(Roche (Switzerland))
Cited by 0
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Lung cancer: current therapies and new targeted treatments
|The Lancet|2016|3.3k
First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer
|New England Journal of Medicine|2014|3.2k
Alectinib versus Crizotinib in Untreated <i>ALK</i>-Positive Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2017|2.4k